


OARV-771

Cat. No.:	HY-145264
CAS No.:	2683008-37-7
Molecular Formula:	C ₄₉ H ₅₉ ClN ₈ O ₈ S ₂
Molecular Weight:	987.62
Target:	Epigenetic Reader Domain; PROTACs
Pathway:	Epigenetics; PROTAC
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (101.25 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	1.0125 mL	5.0627 mL	10.1254 mL	
		5 mM	0.2025 mL	1.0125 mL	2.0251 mL	
		10 mM	0.1013 mL	0.5063 mL	1.0125 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.53 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.53 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.53 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	OARV-771 is a VHL-based BET degrader (PROTAC) with improved cell permeability. OARV-771 shows DC ₅₀ s of 6, 1, and 4 nM for Brd4, Brd2 and Brd3, respectively ^[1] .			
IC ₅₀ & Target	BRD4 6 nM (DC50)	BRD2 1 nM (DC50)	BRD3 4 nM (DC50)	VHL
In Vitro	OARV-771 shows antiproliferative effect with an EC ₅₀ value of 4 nM in MV4;11 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Klein VG, et al. Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity. J Med Chem. 2021;64(24):18082-18101.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA